Heterocyclic compounds and their preparation and pharmaceutical
申请人:Glaxo, S.p.A.
公开号:US05162345A1
公开(公告)日:1992-11-10
Compounds are described of the formula: ##STR1## and physiologically acceptable salts thereof, in which R.sub.1 -R.sub.7 are defined hereinafter. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion concentration and thus may be useful for the treatment of cardiovascular disorders such as hypertension.